Target intelligence / Profile preview

Transmembrane protein 240 (TMEM240)

Target
TMEM240
Molecular classification
Other (membrane protein, not classified as receptor, ion channel, enzyme, or transporter)
01

Overview

Transmembrane protein 240 (TMEM240) is a small, evolutionarily conserved membrane protein encoded by the TMEM240 gene (previously C1orf70), located on chromosome 1p36.33[5][7][8]. It is highly expressed in brain tissue, particularly in the cerebellum and other regions involved in motor control[3][4][5]. Mutations in TMEM240 cause spinocerebellar ataxia type 21 (SCA21), a rare autosomal dominant neurodegenerative disorder characterized by early-onset, slowly progressive cerebellar ataxia, cognitive impairment, and variable neurodevelopmental delay[2][4][6][8]. The exact physiological and molecular function of TMEM240 remains unclear, but it is believed to play a role in neuronal structure and function. Pathogenic variants (typically missense or nonsense mutations) disrupt normal protein function, leading to the SCA21 phenotype[2][6][8]. TMEM240 is not currently considered a therapeutic target, and no drugs are known to modulate its activity for disease treatment.

Other names
C1orf70SCA21transmembrane protein C1orf70TMEM240transmembrane protein 240
02

Mechanism of action

No established drugs; mechanism of pathogenesis is through gene mutations leading to protein dysfunction causing SCA21.

03

Biological functions

Neural developmentNeuronal homeostasisUnknown/under investigation (the specific molecular function remains to be clarified)
04

Disease associations

Neurodegenerative disease (Spinocerebellar ataxia 21/SCA21)Intellectual disabilityNeurodevelopmental disorder

Beyond the preview

Go deeper on Transmembrane protein 240 (TMEM240).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transmembrane protein 240 (TMEM240).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call